利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.021 秒)

    TREATMENT FOR PRE-ECLAMPSIA IN PREGNANT WOMEN USING TARGETED APHERESIS
    1.
    发明申请
    TREATMENT FOR PRE-ECLAMPSIA IN PREGNANT WOMEN USING TARGETED APHERESIS 审中-公开
    孕激素治疗孕激素治疗前列腺炎

    公开(公告)号：US20100247650A1

    公开(公告)日：2010-09-30

    申请号：US12415585

    申请日：2009-03-31

    申请人： Henry J. Smith ,  James R. Smith

    发明人： Henry J. Smith ,  James R. Smith

    IPC分类号： A61K9/10 ,  A61K39/395 ,  A61K38/18

    CPC分类号： C07K16/2863 ,  A61K2039/505 ,  A61M1/3472 ,  A61M1/3489

    摘要： This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby the sFlt-1 receptors responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing either immobilized PIGF, and/or through a cartridge containing immobilized anti-sFlt-1 antibody. The sFlt-1 receptor is bound out and the cleaned blood is returned to the patient Removal of circulating sFlt-1 receptors will diminish the risk of developing eclampsia during pregnancy.

    摘要翻译： 本发明使用“靶向单采”来治疗处于发生子痫危险的孕妇。 “靶向单采”是指通过使血液通过含有固定化PIGF的药筒，和/或通过含有固定化的抗sFlt-1的药筒的药物，通过将血液通过含有固定化PIGF的药筒，选择性地从血液中除去引起疾病症状的sFlt-1受体 抗体。 sFlt-1受体被结合，清洁的血液返回给患者。循环sFlt-1受体的去除将降低怀孕期间发生子痫风险。

    Multi-Drug Lipsomes to Treat Tumors
    2.
    发明申请
    Multi-Drug Lipsomes to Treat Tumors 审中-公开

    公开(公告)号：US20190022005A1

    公开(公告)日：2019-01-24

    申请号：US16115973

    申请日：2018-08-29

    申请人： Henry J. Smith ,  James R. Smith

    发明人： Henry J. Smith ,  James R. Smith

    IPC分类号： A61K9/127

    摘要： A process for treating tumors by administering a mixture of cancer fighting drugs incorporated into a stabilized liposomal formulation. Each cancer drug is selected to target a different phase of the cell-cycle of the cancer cell thus expanding the number of cancer cells that can be killed at one time without compromising the safety of the patient. The stabilized multi-drug liposomes are designed to extravasate thru “leaky” blood capillaries supplying the tumor and enter the tumor tissue where they will accumulate over time and ultimately release the mixture of cancer drugs to kill surrounding tumor cells. The multi-drug liposomes are likewise unable to extravasate thru normal blood capillaries and will thus be less toxic to normal tissues.

    TUMOR TREATMENT USING CYTOKINES AND CANCER DRUGS
    6.
    发明申请
    TUMOR TREATMENT USING CYTOKINES AND CANCER DRUGS 有权

    公开(公告)号：US20220008511A1

    公开(公告)日：2022-01-13

    申请号：US16926767

    申请日：2020-07-12

    申请人： Henry J. Smith

    发明人： Henry J. Smith

    IPC分类号： A61K38/19 ,  A61K9/00 ,  A61K47/69 ,  A61K38/17 ,  A61K38/18 ,  A61K38/40 ,  C07K16/22 ,  C07K16/28

    摘要： This invention discloses a pharmaceutical composition for treating tumors wherein said pharmaceutical comprises a proinflammatory cytokine such as Tumor Necrosis Factor alpha (TNF-a) combined with one or more small molecule cancer drugs within the same liposome. The liposomes are sized to be below 250 nm in diameter to enable them to localize within the tumor due to the Enhanced Permeability and Retention (EPR) effect. This liposomal formulation will ensure that the proinflammatory cytokine and the cancer drug are localized together within the tumor and with less exposure to normal tissues. This invention also discloses that the safety and efficacy of said proinflammatory cytokine/drug liposomes could be further enhanced by coating the exterior of said liposomes with a tumor targeting agent.

    CALIBRATED ASSEMBLY FOR IR THERMOMETER APPARATUS
    7.
    发明申请
    CALIBRATED ASSEMBLY FOR IR THERMOMETER APPARATUS 有权
    红外温度计装置的校准装配

    公开(公告)号：US20100265986A1

    公开(公告)日：2010-10-21

    申请号：US12426556

    申请日：2009-04-20

    申请人： Matthew D. Mullin ,  Michael J. Anson ,  John A. Lane ,  David E. Quinn ,  Henry J. Smith ,  Ray D. Stone

    发明人： Matthew D. Mullin ,  Michael J. Anson ,  John A. Lane ,  David E. Quinn ,  Henry J. Smith ,  Ray D. Stone

    IPC分类号： G01K15/00 ,  G01J5/10

    CPC分类号： G01J5/061 ,  G01J5/0003 ,  G01J5/0011 ,  G01J5/02 ,  G01J5/021 ,  G01J5/025 ,  G01J5/04 ,  G01J5/049

    摘要： A tip assembly for an IR thermometer apparatus includes a heat sink having a heat sink cavity and a tip section and a fluid path and at least one hydraulic port. The tip assembly also includes an IR sensor mechanically seated in the tip section and thermally coupled to the heat sink. The tip assembly also includes an electrical connector configured to provide an electrical connection to the tip assembly. A fluid having a fluid temperature is introduced into the fluid path via the hydraulic port. The fluid causes the heat sink and the IR sensor to substantially reach one or more pre-determined temperatures by thermal conduction during calibration of the tip assembly. Another tip assembly having an internal heat source is described. Another tip assembly having an internal heat pump is described. A method to calibrate a tip assembly is also described.

    摘要翻译： 用于IR温度计装置的尖端组件包括具有散热器腔和顶端部分以及流体路径和至少一个液压端口的散热器。 尖端组件还包括机械地安置在尖端部分中并热耦合到散热器的IR传感器。 尖端组件还包括被配置为提供与尖端组件的电连接的电连接器。 具有流体温度的流体经由液压口引入到流体路径中。 流体导致散热器和IR传感器在尖端组件的校准期间通过热传导基本上达到一个或多个预定温度。 描述具有内部热源的另一个尖端组件。 描述了具有内部热泵的另一个尖端组件。 还描述了校准尖端组件的方法。

    Luminescent paintball for marking nighttime impacts
    8.
    发明授权
    Luminescent paintball for marking nighttime impacts 失效
    用于标记夜间影响的发光彩弹

    公开(公告)号：US5018450A

    公开(公告)日：1991-05-28

    申请号：US514302

    申请日：1990-04-25

    申请人： Henry J. Smith

    发明人： Henry J. Smith

    IPC分类号： F42B12/40

    CPC分类号： F42B12/40 ,  Y10S273/24

    摘要： For use in marking nighttime impacts from easily ruptured paintball type projectiles that are fired from compressed air guns; this invention provides a double chamber projectile capsule that contains two chemical agents which, when mixed together on impact, provide a luminescent spot to visibly mark impacts at night; for police and military training, as well as the popular adult war games, based on the present paint ball and air gun equipment.The unique modifications are designed to fit into the present standardized paintball specifications, without adding unusual expense. A double barrier feature assures necessary shelf life and complete separation of the reactive agents; as well as increased ease of loading the two chemical agents during manufacture.

    摘要翻译： 用于标记从压缩空气枪射出的容易破裂的彩弹射弹的夜间冲击; 本发明提供了一种双室射弹胶囊，其包含两种化学试剂，当在冲击下混合在一起时，提供亮点以可见地标记夜间的冲击; 根据目前的油漆球和喷枪设备，进行警察和军事训练，以及受欢迎的成人战争游戏。 独特的修改旨在适应现行的标准化彩弹规格，而不会增加不寻常的费用。 双重屏障功能确保了必要的保质期和反应剂的完全分离; 以及在制造过程中增加两种化学试剂的容易性。

    OPTIMIZING DRUG DELIVERY
    9.
    发明申请
    OPTIMIZING DRUG DELIVERY 有权

    公开(公告)号：US20210008215A1

    公开(公告)日：2021-01-14

    申请号：US16505474

    申请日：2019-07-08

    申请人： Henry J. Smith

    发明人： Henry J. Smith

    IPC分类号： A61K47/24 ,  A61K9/107

    摘要： This invention teaches a method of increasing the bioavailability, safety and efficacy of a cancer drug incorporated in a nanocarrier such as liposomes, micelles, dendrimeres, nanoemulsion, nanoparticles and antibody drug conjugates. It does so by administering pre-blocking blank liposomes to the patient several hours before the drug incorporated nanocarrier is administered. Blocking the reticuloendothelial system (RES) will prevent it from taking up the drug incorporated nanocarrier and hence improve the safety and efficacy of the drug.

    APHERESIS TO REDUCE HIGH BLOOD PRESSURE IN PRE-ECLAMPSIA
    10.
    发明申请
    APHERESIS TO REDUCE HIGH BLOOD PRESSURE IN PRE-ECLAMPSIA 审中-公开

    公开(公告)号：US20200069861A1

    公开(公告)日：2020-03-05

    申请号：US16432771

    申请日：2019-06-05

    申请人： Henry J. Smith

    发明人： Henry J. Smith

    IPC分类号： A61M1/36 ,  A61M1/34

    摘要： There are certain factors in the blood of pregnant women with pre-eclampsia that appear to be associated with the disease. These include a soluble variant of the fms-like tyrosine kinase receptor (sFlt-1), soluble Endoglin (sEndoglin), and Endothelin-1. There is also evidence that hypertension may be caused by Na/K ATPase inhibitors such as digitalis-like factor, ouabain-like factors, marinobufogenin and marinobufotoxin. This invention teaches the removal of multiple harmful factors using a combination of targeted apheresis and dialysis and/or ultrafiltration. Harmful factors that are proteins are bound out using immobilized binding agents such as antibodies, aptamers and binding peptides, while small molecule harmful factors are dialyzed out or filtered out. Removal of multiple harmful factors is expected to ameliorate the symptoms of pre-eclampsia and prolong pregnancy.